Key result
An alternative anticoagulant targeted therapy regimen reduced the incidence of acute renal failure by 90% and infectious complications by 60% in the early postoperative period after LVAD implantation.
Why the study?
Optimizing antithrombotic therapy and preventive strategies is critical for managing common non-surgical complications such as infections, brain lesions, and acute renal failure in the early postoperative period after LVAD implantation.
Does alternative anticoagulant targeted therapy compared to classical therapy affect the incidence of non-surgical complications in patients with implanted LVADs in the early postoperative period?
Observational (n=10)
No
Does alternative anticoagulant targeted therapy compared to classical therapy affect the incidence of non-surgical complications in patients with implanted LVADs in the early postoperative period?
In a small cohort of LVAD patients, non-surgical complications such as infections and neurological events were common in the early postoperative period, highlighting the need for optimized antithrombotic and preventive strategies.
The work was performed within the framework of a bilateral agreement on scientific cooperation between the NMAPE named P.L. Shupyk (Department of Anesthesiology & Intensive Care) and the Silesian Center for Heart Disease (Poland).Resume. The work is devoted to the study of infectious, nephrotic, neurological, pulmonary aortic, right ventricle and other complications in the early postoperative period in ten patients with implanted left ventricle assist devices (LVAD). The most common non-surgical complications include infections, ischemic-hemorrhagic lesions of the brain that arise in the postoperative period of acute renal failure. Conducting optimal antithrombotic therapy in such patients is an important method of treatment, especially in the early postoperative period. Most of the infectious complications develop in the exit places of the power cable of the implanted devices. An individual approach to preventive strategies is critical to improving patient outcomes. This article presents an analysis of complications that developed in the early postoperative period in ten patients with LVAD implanted devices in the Silesian Center for Heart Disease (SCCS), Poland. Patients were divided into two groups in the control group receiving classical anticoagulant targeted therapy (ATT), which included heparin, varfarin and aspirin and the subjects receiving an alternative ATT, that consisted of cropidogrel, thrombin inhibitors in combination with classical anticoagulant target therapy.
No takes yet. Share an insight, caveat, or question.
Mazurenko et al. (2019) conducted an observational in Severe heart failure requiring LVAD (n=10). Alternative anticoagulant targeted therapy (clopidogrel, thrombin inhibitors, and classical ATT) vs. Classical anticoagulant targeted therapy (heparin, warfarin, aspirin) was evaluated on Incidence of acute renal failure and infectious complications. An alternative anticoagulant targeted therapy regimen reduced the incidence of acute renal failure by 90% and infectious complications by 60% in the early postoperative period after LVAD implantation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: